Albireo Pharma (ALBO) PT Raised to $82 at Jefferies Ahead of Odevixibat Approval
Tweet Send to a Friend
Jefferies analyst Eun Yang raised the price target on Albireo Pharma (NASDAQ: ALBO) to $82.00 (from $79.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
